The H2BC12L Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the H2BC12L gene in the HeLa human cervical adenocarcinoma cell line. This polyclonal format introduces loss-of-function mutations across a bulk pool of cells, generating a heterogeneous gene-edited model that captures population-level chromatin dynamics without isolating single-cell clones. The product serves as a versatile tool for probing histone variant-specific functions in nucleosome assembly and genomic stability, leveraging the power of CRISPR/Cas9 technology to interrogate replication-dependent histone biology.
The HeLa host cell line originates from an HPV18-positive cervical adenocarcinoma and is characterized by inactivation of the p53 and Rb tumor suppressor pathways. These features confer a highly proliferative phenotype with substantial genetic instability, making HeLa cells a cornerstone model in cancer research, virology, and cell cycle studies. The rapid division rate of HeLa cells imposes a high demand for histone biosynthesis during S phase, rendering this background especially relevant for investigating replication-linked histone functions and their impact on chromatin architecture.
H2BC12L encodes a replication-dependent histone H2B variant that is integrated into the nucleosome core particle alongside H2A, H3, and H4 to form the histone octamer. Its expression is tightly controlled by E2F transcription factors and Cyclin E/CDK2 signaling during S phase, ensuring coordinated histone supply with DNA replication. The H2B protein interacts directly with histone chaperones such as NAP1L1 and SPT16, and interfaces with chromatin assembly complexes including CAF-1 and ASF1. Disruption of H2BC12L thus perturbes nucleosome assembly, leading to altered chromatin compaction and defects in replication-coupled nucleosome dynamics, which can provoke DNA replication stress and global gene expression changes.
In the HeLa cellular context, knockout of H2BC12L is predicted to exacerbate inherent genomic instability due to compromised DNA damage checkpoints. The loss of this histone variant disrupts the stoichiometric balance of the histone octamer, potentially causing defective chromatin compaction, aberrant histone modification landscapes, and impaired cell cycle progression. This model therefore provides a critical platform for dissecting how replication-dependent histone deposition maintains genome integrity in cancer cells, and for exploring synthetic lethal interactions arising from combined chromatin dysfunction and checkpoint deficiencies.
This polyclonal knockout product supports a broad spectrum of experimental applications, including Western blotting to assess histone protein levels, ChIP-qPCR for profiling histone modifications, flow cytometry to monitor cell cycle distributions, and immunofluorescence to visualize chromatin markers. Transcriptome-wide RNA-seq and comet assay-based DNA damage quantification offer complementary insights into the downstream consequences of H2BC12L loss. Together, these approaches enable rigorous investigation into cancer epigenetics, replication stress biology, and chromatin organization. For further details or technical consultation, please contact Ascent Research.
